Abstract
Activation of the NLRP3-inflammasome has been proposed to play a role in Parkinson’s disease pathogenesis based on in vitro and in vivo studies. Currently, clinical trials targeting the NLRP3 pathway in Parkinson’s disease are at early stages. However, the evidence supporting NLRP3’s involvement in Parkinson’s disease from human genetics data remains limited. In this study, we conducted comprehensive analyses of common and rare variants in genes related to the NLRP3-inflammasome in large Parkinson’s disease cohorts. Furthermore, we performed pathway-specific analyses using polygenic risk scores and studied potential causal associations using Mendelian randomization with the NLRP3 components and the cytokines released by its activation, IL-1β and IL-18. Our findings showed no associations of common or rare variants, nor of the pathway polygenic risk score for the NLRP3 inflammasome, with risk of Parkinson’s disease. Mendelian randomization analyses suggest that altering the expression of the NLRP3 inflammasome, IL-1β or IL-18, is not likely to affect Parkinson’s disease risk, age-at-onset, or progression. Therefore, our results do not support an important role for the NLRP3 inflammasome in Parkinson’s disease pathogenesis or as a strong target for drug development.
Competing Interest Statement
Z.G.O received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanquabio Guidepoint, Lighthouse and Deerfield. C.X.A., M.A.N. and HL.L.′s participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research. M.A.N. also currently serves on the scientific advisory board for Character Bio Inc. and as an advisor to Neuron23 Inc.
Funding Statement
This work was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of McGill University gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript. Data used in the preparation of this article were obtained from the AMP PD Knowledge Platform and are available for qualified researchers. For up-to-date information on the study, visit https://www.amp-pd.org. The full GWAS summary statistics for the 23andMe discovery data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit research.23andme.com/collaborate/ for more information and to apply to access the data.
Abbreviations
- NLRP3
- nucleotide-binding oligomerization domain-, leucine-rich repeat, and pyrin domain-containing 3
- CASP1
- caspase-1
- PRS
- polygenic risk scores
- MR
- Mendelian randomization
- IL-1β
- interleukin-1 beta
- IL-18
- interleukin-18
- GWAS
- genome-wide association study
- LD
- linkage disequilibrium
- SNP
- single nucleotide polymorphism
- PRSet
- Polygenic Risk Score Estimation Tool
- SKAT-O
- sequence kernel association test optimized
- AMP-PD
- Accelerating Medicines Partnership – Parkinson Disease
- UKBB
- UK Biobank
- GATK
- Genome Analysis Toolkit
- QTL
- quantitative trait loci
- SMR
- summary-data-based Mendelian Randomization
- GTEx
- Genotype-Tissue Expression
- MMSE
- Mini-Mental State Examination
- MoCA
- Montreal Cognitive Assessment
- UPDRS
- Unified Parkinson’s Disease Rating Scale
- CADD
- combined annotation dependent depletion
